Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Sees Significant Decline in Short Interest

Posted by on Oct 2nd, 2026

Catheter Precision, Inc. (NYSEAMERICAN:VTAK – Get Free Report) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 228,199 shares, a drop of 42.8% from the August 31st total of 398,714 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average trading volume of 934,294 shares, the days-to-cover ratio is presently 0.2 days.

Catheter Precision Stock Performance

VTAK traded down $0.00 during trading on Friday, hitting $0.15. The company’s stock had a trading volume of 222,596 shares, compared to its average volume of 4,125,662. Catheter Precision has a one year low of $0.13 and a one year high of $3.20. The business’s 50 day simple moving average is $0.21 and its 200-day simple moving average is $0.68. The company has a quick ratio of 0.18, a current ratio of 0.19 and a debt-to-equity ratio of 0.19. The firm has a market cap of $2.14 million, a PE ratio of -0.02 and a beta of -0.99.

Catheter Precision shares are going to reverse split before the market opens on Monday, October 5th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 4th.

Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($19.00) by $18.08. The firm had revenue of $1.02 million during the quarter, compared to analyst estimates of $2.00 million. Catheter Precision had a negative return on equity of 37.53% and a negative net margin of 656.03%.

About Catheter Precision

(Get Free Report)

Catheter Precision, Inc is a medical device company focused on developing technologies for electrophysiology procedures used to diagnose and treat cardiac arrhythmias. Its products are designed to support physicians during catheter-based cardiac procedures, particularly those involving ventricular arrhythmias.

The company’s portfolio includes the VIVO system, a noninvasive cardiac mapping platform intended to help physicians identify the origin of ventricular arrhythmias and plan catheter ablation procedures.

Featured Articles

Receive News & Ratings for Catheter Precision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catheter Precision and related companies with MarketBeat.com's FREE daily email newsletter.